Dasatinib Plus Peg-IFN-Alpha2b Appears Safe, Effective in Patients With Newly Diagnosed CML
Researchers sought to determine whether combining dasatinib and Peg-IFN-alpha2b would be an effective treatment for patients with newly diagnosed CML.
Chronic Myeloid Leukemia
Asciminib Improves MMR, Toxicity Compared With Bosutinib in CML-CP
Researchers sought to determine whether asciminib would be superior to bosutinib in patients with chronic myeloid leukemia in chronic phase.
Guidelines for CML Not Followed in the Real World
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
Two-Step Strategy Promising in TKI Dose Reduction in Chronic Myeloid Leukemia
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
FLAG-IDA May Induce Second Chronic Phase in Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether treatment with FLAG-IDA could induce a second chronic phase in patients with CML.
Asciminib Shows Superior Efficacy to Bosutinib for Patients With CML in Chronic Phase
Researchers sought to determine whether asciminib would be better than bosutinib for treating patients with chronic myeloid leukemia in chronic phase.
Chronic Myeloid Leukemia: 5 Myths You May Encounter
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
Algorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated CML
Researchers sought to determine the accuracy of established cardiovascular assessment tools in predicting risk of CV events in patients with CML receiving TKIs.
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
- Loading...
Loading...
Loading... 
Loading...